Pieris Pharmaceuticals, INC Form 4 insider transactions

Jeffrey S. Martini, Chief Scientific Officer of Palvella Therapeutics, acquires incentive and non-qualified stock options.

Matthew E. Korenberg, CFO and Treasurer of Palvella Therapeutics, received incentive and non-qualified stock options on February 5, 2025.

Wes Kaupinen, President and CEO of Palvella Therapeutics, acquires 243,831 non-qualified stock options.

Kathleen Goin, COO of Palvella Therapeutics, was granted incentive and non-qualified stock options on February 5, 2025.

George M. Jenkins, a director at Palvella Therapeutics, purchased 4,000 shares of common stock at a weighted average price of $12.93.

Director Elaine J. Heron of Palvella Therapeutics acquired 24,700 stock options on December 13, 2024, which vest over three years.

Director Tadd S. Wessel acquired 24,700 stock options in Palvella Therapeutics on December 13, 2024.

A director of Palvella Therapeutics, Todd C. Davis, acquired 24,700 stock options on December 13, 2024.

Palvella Therapeutics' Chief Scientific Officer, Jeffrey S. Martini, was granted 126,416 stock options on December 13, 2024.

Palvella Therapeutics' Chief Operating Officer, Kathleen Goin, was granted 27,843 stock options on December 13, 2024, which vest over 48 months.

Palvella Therapeutics CFO, Matthew Korenberg, acquired 167,100 stock options on December 13, 2024, which will vest over the next 3 years.

A Palvella Therapeutics director, George M. Jenkins, acquired 24,700 stock options on December 13, 2024.

Palvella Therapeutics' CEO, Wes Kaupinen, was granted 417,806 stock options on December 13, 2024, which vest over 48 months.

Christopher P. Kiritsy, a director at Palvella Therapeutics, acquired 24,700 stock options on December 13, 2024.

BVF Partners and related entities acquired shares of Palvella Therapeutics common stock and convertible preferred stock following a reverse merger with Pieris Pharmaceuticals.

Dellora Investments LP is no longer a 10% shareholder in Palvella Therapeutics following the completion of a merger and financing on December 13, 2024.

James A. Geraghty, a director at Pieris Pharmaceuticals, redeemed his Series F Preferred Stock for $0.01 following the effectiveness of an Authorized Share Increase.

Pieris Pharmaceuticals' stockholders approved a merger with Palvella Therapeutics, an increase in authorized shares, and a new equity incentive plan at a special meeting on December 11, 2024.

A director of Pieris Pharmaceuticals, Christopher P. Kiritsy, acquired 500 stock options on December 2, 2024.

Pieris Pharmaceuticals provides supplemental disclosures regarding its merger with Palvella Therapeutics, addressing stockholder demands and lawsuits alleging disclosure deficiencies.

Palvella Therapeutics has dosed the first patient in its Phase 3 clinical trial, SELVA, evaluating QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations (microcystic LMs).

Director James A. Geraghty purchased one share of Series F Preferred Stock in Pieris Pharmaceuticals on August 7, 2024.

Palvella Therapeutics, a clinical-stage biopharmaceutical company, has appointed Matthew E. Korenberg as its Chief Financial Officer, effective immediately.

Palvella Therapeutics will present data supporting QTORIN rapamycin 3.9% anhydrous gel as a potential treatment for microcystic lymphatic malformations at the upcoming PeDRA Annual Conference.

Palvella Therapeutics receives a grant of up to $2.6 million from the FDA to support its Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations.

ADAR1 Capital Management, a significant shareholder in Pieris Pharmaceuticals, has reported further acquisitions of common stock.

Pieris Pharmaceuticals issued a single share of Series F Preferred Stock to its Chairman, James Geraghty, for $1.00 to ensure a favorable vote on a future proposal to increase the company's authorized common stock.

Pieris Pharmaceuticals and Palvella Therapeutics have announced a definitive merger agreement to form a clinical-stage biopharmaceutical company focused on rare genetic skin diseases.